Quantcast
Last updated on April 24, 2014 at 16:01 EDT

Latest Anticonvulsants Stories

2011-10-31 15:45:00

The Consumer Justice Foundation is a for-profit corporation thatâs comprised of a team of professional consumer advocates who work to provide information regarding dealing with large insurance companies and regarding the dangers of certain prescription medications by way of providing free online resources to consumers. The CJF, whose Web site URL can be found at http://www.depakotebirthinjury.com, hereby alerts the public and those who may have been harmed by Depakote side...

2011-10-24 09:34:00

SILVER SPRING, Md., Oct. 24, 2011 /PRNewswire-USNewswire/ -- On Oct. 21, the U.S. Food and Drug Administration approved Onfi tablets (clobazam) for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older. As Onfi is intended to treat a disease or condition that affects fewer than 200,000 people in the United States, it was granted orphan drug designation by the FDA. (Logo:...

2011-10-11 05:30:00

ANAHEIM, Calif., Oct. 11, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release third quarter 2011 financial results on Tuesday, October 25, 2011 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, October 25, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the third quarter, as well as current corporate developments....

2011-09-26 08:40:00

MAPLE GROVE, Minn., Sept. 26, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced the presentation of Phase I data showing that once daily administration of USL255, a proprietary extended-release (ER) formulation of the epilepsy medication topiramate, demonstrated equivalent topiramate exposure to immediate-release (IR) topiramate dosed twice daily. These findings were presented Monday, September 26, at the American Neurological...

2011-09-26 05:45:00

MOUNTAIN VIEW, Calif., Sept. 26, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that a poster authored by Dr. Mark W. Green, Director of the Center for Headache and Pain Medicine and Professor of Neurology and Anesthesiology at the Mount Sinai School of Medicine, will be presented at the American Neurological Association (ANA) Meeting in San Diego, CA. In addition to the topiramate exposure data previously reported, the results will include the rate of major congenital...

2011-09-06 08:25:00

EXTON, Pa., Sept. 6, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted a Centralized Pediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years of age. This action by the European Commission represents the first product approval...

2011-09-01 11:57:02

New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control seizures. The research is published in the August 31, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology. "Despite some limitations, our results suggest that the choice of seizure medications in brain tumor patients should be carefully considered as it...

2011-09-01 04:20:02

Looks to Expand Global Epilepsy Product Portfolio Tokyo, Sept 1, 2011 - (JCN Newswire) - Eisai Co., Ltd. announced today that 35 abstracts highlighting the latest results from studies with its pipeline and portfolio products (perampanel: 5 abstracts, Zonegran(R): 5 abstracts, Zebinix(R): 25 abstracts) were presented at the 29th International Epilepsy Congress which took place in Italy (Rome) between August 28 and September 1, 2011. This research demonstrates...

2011-07-25 08:00:00

MAPLE GROVE, Minn., July 25, 2011 /PRNewswire/ -- In a comparative pharmacokinetic (PK) study, Upsher-Smith Laboratories' USL255, a new, once-daily extended-release formulation of topiramate in development for the management of epilepsy in adults, was shown to be bioequivalent to twice-daily immediate-release topiramate (Topamax®*) in its extent of absorption. Furthermore, USL255, administered with or without food, demonstrated a slower absorption profile compared with...

2011-07-20 05:45:00

MOUNTAIN VIEW, Calif., July 20, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress (IEC) in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated...